2025 Total Revenue of $241.6 million (approximately $315.0 million including Bayswater), an increase of approximately 3,000% year-over-year Record Adjusted EBITDA(1) of $155.5 million (approximately $220.0 million including Bayswater), an increase of over 975% year-over-year Approximately 3,900% increase in annual production to 18,500 net Boe/d (approximately 24,000 Boe/d including Bayswater) (50% oil / 73% liquids) Current production rate of approximately 28,000 net Boe/d Reached agreement to extend grant of Series F Preferred equity anniversary warrantsHOUSTON, March 30, 2026 (GLOBE NEWSWIRE) — Prairie Operating Co. (Nasdaq: PROP) (the “Company,” “Prairie,” “we,” “our,” or “us”) – an independent energy company engaged in the development and acquisition of oil, natural gas, and natural gas liquids (“NGL”) resources in the...

REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter and year ended December 31, 2025 and provided a corporate update. “Briquilimab has demonstrated the potential for a compelling and differentiated profile in both CSU and CIndU, along with proof of concept in asthma,” said Jeet Mahal, President and Chief Executive Officer of Jasper. “We are very pleased with the chronic urticaria data we reported in January from the BEACON study as well the open-label extension study,...

Company to Host Conference Call Today, March 30, at 4:30pm ET BOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announces its financial results for the year ended December 31, 2025 and provides a business update. Recent Corporate Highlights CORDStrom™ Platform:The CORDStrom™ program in recessive dystrophic epidermolysis bullosa (RDEB) is on target to file an MAA submission in the UK mid-summer, followed shortly thereafter by anticipated EMA and FDA regulatory submissions. Hosted KOL led webinar focused on the latest results from the MissionEB Phase III clinical trial highlighting the systemic disease-modifying capabilities of CORDStrom™ in patients with RDEB. Announced the publishing...

Reports Q4 2025 GAAP Net Loss of $15.5 Million and Full Year Net Loss of $43.9 Million Calculates Q4 2025 Adjusted Net Loss of $8.7 Million (Non-GAAP) and Full Year Adjusted Net Loss of $18.5 Million (Non-GAAP) Recognized $4.2 Million in Other Income for the Full Year, primarily from California Energy Commission Grant Ended Year with $9.6 Million in Cash and Cash EquivalentsCARLSBAD, Calif., March 30, 2026 (GLOBE NEWSWIRE) — Aptera Motors Corp. (NASDAQ: SEV) (“Aptera” or the “Company”), a solar mobility company advancing ultra-efficient transportation, today reported its financial results for the fourth quarter and full year ended December 31, 2025. “Our fourth quarter capped a transformative year for Aptera as we transitioned to a publicly traded company and began standing up our validation assembly line,” said Chris Anthony,...

Commercial inflection with >$50 million in bookings in early 2026 Operating companies advancing independent capital formation, materially reducing reliance on Innventure’s balance sheet Consolidated G&A declined 61% in 4Q25 compared to 4Q24, reflecting sustained cost discipline since the public listing ORLANDO, Fla., March 30, 2026 (GLOBE NEWSWIRE) — Innventure, Inc. (NASDAQ: INV) (“Innventure”), an industrial growth conglomerate, today announced financial results for the quarter and year ended December 31, 2025. “The fourth quarter capped a successful 2025 for Innventure. More importantly, the early months of 2026 demonstrate Innventure is at a true commercial inflection point. Our operating companies are executing simultaneously, converting demand into bookings, raising capital independently, and materially reducing the capital...

NANCHANG, China, March 30, 2026 (GLOBE NEWSWIRE) — Ruanyun Edai Technology Inc. (NASDAQ: RYET) (“Ruanyun” or the “Company”), an innovative artificial intelligence (“AI”) driven education technology company focused on developing and delivering AI-enabled digital education platforms, including intelligent learning tools, assessment platforms, and adaptive learning systems, today announced its unaudited interim financial results for the six months ended September 30, 2025. 1H 2026 (Six Months Ended September 30, 2025) Unaudited Interim Financial HighlightsOur revenue was $366,256 for the six months ended September 30, 2025, compared with $4,109,689 for the six months ended September 30, 2024, representing a decrease of 91.1%. Gross margin was 26.2% for the six months ended September 30, 2025, compared with 42.1% for the six months...

BURLINGTON, Mass., March 30, 2026 (GLOBE NEWSWIRE) — Progress Software (Nasdaq: PRGS), a member of the Russell 2000 Index, today announced its financial results for the fiscal first quarter 2026, which ended on February 28, 2026. Progress is the trusted provider of AI-powered digital experience and infrastructure software. The company’s earnings release and a supplemental slide presentation can be accessed via the Investor Events & Presentations link on the Progress Investor Relations webpage. Progress will host a conference call today at 5:00 p.m. ET to discuss its results and outlook. Conference Call DetailsA live webcast of the call will be available using this link. To access the conference call by phone, please use this link to retrieve dial-in details. To avoid delays, we encourage participants to dial in 15 minutes...

RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 Million on Hand, Company has the Funding, Business Plan, Leadership, and Infrastructure to Drive Growth and Shareholder Value Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., March 30, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced its financial results for the full year and fourth quarter ended December 31, 2025, and is providing a business update to shareholders. Shaun Bagai, Chief...

NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) — Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury (“DAT”) dedicated to acquiring and holding Solana tokens (“SOL”), today announced results for the quarter and full year ended December 31, 2025. Fourth Quarter and Full Year Recent Business UpdatesGenerated $5.1 million in staking rewards in the fourth quarter of 2025 and $5.5 million for the full year, as substantially all SOL holdings were staked throughout the period Raised $29.9 million in 2025 through the Company’s ATM programs, with proceeds used primarily to purchase SOL on an net asset value (“NAV”)/share accretive basis Repurchased $3.4 million of common stock in 2026, funded primarily through the sale of SOL, while NAV/share...

RICHMOND, Va., March 30, 2026 (GLOBE NEWSWIRE) — ARKO Petroleum Corp. (Nasdaq: APC) (“APC” or the “Company”), one of the largest wholesale fuel distributors in the United States, today announced financial results for the fourth quarter and the full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Key Highlights (vs. Year-Ago Period) 1,2Net income for the quarter increased to $8.1 million compared to $7.5 million.  For the year, net income was $32.7 million compared to $40.2 million. Adjusted EBITDA for the quarter increased to $36.9 million compared to $35.4 million.  For the year, Adjusted EBITDA was $143.5 million compared to $139.2 million.   Net cash provided by operating activities for the quarter was $16.4 million compared to $35.1 million.  For the year, net cash provided by operating activities was $79.6...